A comprehensive anti-bribery policy is essential, but not enough
Recently, the FCPA Blog featured the Novartis anti-bribery policy as part of its respective benchmark series. The design and implementation of an effective anti-bribery policy is undoubtedly one of the pillars of every serious compliance program — but it should not be seen as the only one.… Continue Reading